IL3RA and acute myeloid leukemia: AML-engrafted NSG mice showed significantly prolonged survival in mice treated with CD33GO BATs (p < 0.0001) or CD123 BATs (p < 0.0089) compared to ATC-treated control mice. Patient samples containing leukemic blasts and LSCs when treated with CD33GO BATs or CD123 BATs for 18 h showed a significant reduction (50%–100%; p < 0.005) in blasts and 75%–100% reduction in LSCs (p < 0.005) in most cases compared to unarmed ATCs.